Our current research interest is focused on the Plasmodium parasite, the causative agent of Malaria, leading to 300-500 million infections per year and more than 1.2 million deaths worldwide Murray et al. 2012.

The complex life cycle of the malaria parasite involves switching between mosquito and human hosts. Plasmodium is thereby constantly threatened by the host immune system, from which it evades by hiding inside of human liver- and red blood-, as well as mosquito midgut cells. This strategy requires the parasite to traverse various host membranes and undergo dramatic conversion processes to accommodate its rapidly changing environment. In my lab, we are interested in the intricate molecular mechanisms underlying these multiple host cell passages and the metabolic conversion processes in between. 

Using a targeted structure based drug design approach, we employ X-ray crystallography, virtual library screening (VLS), and surface plasmon resonance (SPR) methods to study important key players of these plasmodial mechanisms, with the ultimate aim to develop novel, drug-like compounds to future therapeutic use. Validation of our hit compounds occurs on two levels. The first is using an orthogonal biophysical or biochemical method to the one by which the initial hit was identified and secondly testing in P. falciparum parasites the inhibitory effect of our hit compounds.

For more detailed information visit Malaria Special Edition 2011

The Bosch Lab

Jürgen Bosch, Daisy Colón-López, Lauren Boucher, Alexia MIller, Serge Stamm (October 2014)

updated September 2015

Go to news archiveBlog/Archive.htmlBlog/Archive.htmlshapeimage_2_link_0